Article Sidebar
Published:
Oct 8, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Meta-analysis of the effect of losartan relative to other angiotensin receptor antagonists on serum uric acid level
Abstract
Purpose: To systematically analyze the disparity in uric acid reduction between losartan and other angiotensin receptor antagonists.
Methods: A computer-based search was conducted in databases including EMBASE, PubMed, Wanfang, CNKI, Ovid MEDLINE, and Web of Science to identify original literature comparing the impact of losartan with other angiotensin receptor antagonists on blood uric acid levels. Utilizing the Cochrane Collaboration bias risk tool, a quality assessment of the included randomized controlled studies was conducted.
Results: A total of 12 publications were obtained, consisting of 6 randomized controlled studies and 6 cohort studies. Five of the twelve publications assessed the impact of losartan compared to valsartan on blood uric acid levels. The heterogeneity analysis yielded I2 = 98 % (p < 0.01), indicating substantial variability among the studies. Findings indicated that losartan was more effective than valsartan in reducing blood uric acid levels (SMD = -3.26, 95 % CI (-5.01 to 1.51), p < 0.05). Four publications investigated the impact of losartan versus telmisartan on blood uric acid levels. The results revealed that losartan had a greater effect in reducing blood uric acid levels compared to telmisartan (SMD = -1.77, 95 % CI (-3.411 to -0.13), p < 0.05).
Conclusion: Among the angiotensin receptor antagonists used as antihypertensive drugs, losartan stands out for its significant ability to reduce uric acid levels. This finding provides a strong evidencebase for making clinical medication decisions.
